Metronomic scheduling: the future of chemotherapy?

The Lancet Oncology
G Gasparini

Abstract

Tumour endothelium is a new target for anticancer treatments. Proliferating endothelial cells from the tumour, even if qualitatively different from those of blood vessels in the normal tissue of origin, remain putatively normal and genetically stable cells. The results of recent experimental studies have suggested that frequent administration of certain cytotoxic agents at low doses (a tenth to a third of the maximum tolerated dose), known as 'metronomic' chemotherapy, increases the antiangiogenic activity of the drugs. The effects of these metronomic schedules of cytotoxic agents may be further enhanced by concurrent administration of novel, selective, treatments that inhibit, at a molecular level, the processes of tumour formation and growth eg angiogenesis, growth factor pathways, and other signal transduction cascades. The need to treat patients for long periods also supports the use of metronomic scheduling for chemotherapy, to minimise toxicity and to target both proliferating tumour cells and endothelial cells. This review describes the experimental studies involving metronomic schedules of chemotherapy, alone and in combination with angiogenesis inhibitors, and suggests a new therapeutic anticancer paradigm for controll...Continue Reading

References

May 28, 1992·The New England Journal of Medicine·R A EzekowitzJ Folkman
Jan 1, 1991·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·R S Kerbel
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E EngelsmanR Sylvester
Nov 1, 1990·Cancer Metastasis Reviews·J Denekamp
Sep 1, 1986·Cancer Research·M J Ratain, N J Vogelzang
Nov 18, 1971·The New England Journal of Medicine·J Folkman
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G Gasparini, A L Harris
Oct 1, 1994·Molecular Reproduction and Development·P J HertzogI Kola
Jun 1, 1996·Nature Medicine·M S O'ReillyJ Folkman
Nov 25, 1997·Current Opinion in Oncology·W D KlohsA J Kraker
Dec 6, 1997·Nature·R S Kerbel
Sep 29, 1999·Cancer Chemotherapy and Pharmacology·M K ClementsS S Daoud
Feb 26, 2000·Carcinogenesis·R S Kerbel
Apr 20, 2000·The Journal of Clinical Investigation·D HanahanE Bergsland
May 10, 2000·Cancer Chemotherapy and Pharmacology·C T HsuehG K Schwartz
Aug 19, 2000·Science·B St CroixK W Kinzler
Sep 6, 2000·Nature Medicine·R A Gupta, R N DuBois
Jul 19, 2001·Journal of the National Cancer Institute·I J Fidler

❮ Previous
Next ❯

Citations

Jun 23, 2009·Cancer Chemotherapy and Pharmacology·J Lee VillanoLinda R Bressler
Mar 19, 2009·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·P Khosravi ShahiG Pérez Manga
Mar 14, 2003·Critical Reviews in Oncology/hematology·T M MoehlerB Barlogie
Mar 12, 2004·Critical Reviews in Oncology/hematology·Alessandro MorabitoGiampietro Gasparini
Oct 14, 2003·The Lancet Oncology·Giampietro GaspariniAlessandro Morabito
Jul 20, 2002·Current Opinion in Pharmacology·Srinivasan Madhusudan, Adrian L Harris
Jan 16, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Thomas VielAndreas H Jacobs
Jun 2, 2004·Nature Reviews. Cancer·Robert S Kerbel, Barton A Kamen
Jun 10, 2010·Nature Reviews. Clinical Oncology·Eddy PasquierNicolas André
May 5, 2011·Integrative Biology : Quantitative Biosciences From Nano to Macro·G S PatelT Ng
Feb 18, 2003·Journal of Internal Medicine·P Nygren, R Larsson
Dec 16, 2005·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Jens GilleRoland Kaufmann
May 5, 2009·Cancer Biotherapy & Radiopharmaceuticals·You-shui GaoXuan-song Cai
Jan 8, 2013·Journal of Biochemistry·Kyoko HidaYasuhiro Hida
Jun 12, 2012·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·Chao ChenShenhong Wu
Jan 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jian QiaoKevin Harrington
Aug 14, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert J LechleiderJames L Gulley
Jun 14, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sun Joo LeeAnil K Sood
Apr 18, 2008·Onkologie·Roberta Sarmiento, Giampietro Gasparini
May 26, 2011·Journal of Translational Medicine·Ioannis AlagkiozidisGeorge Coukos
May 27, 2006·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Nicole EterFrank G Holz
Aug 28, 2013·Indian Journal of Cancer·N André, E Pasquier
Aug 28, 2013·Indian Journal of Cancer·V NoronhaK Prabhash
Jul 27, 2012·Future Oncology·Enrico Pierluigi SpugniniAlfonso Baldi
Mar 12, 2013·Cancer Chemotherapy and Pharmacology·Adriana RomitiPaolo Marchetti
Aug 8, 2008·Annals of Surgical Oncology·Charlotte F J M PeetersTheo J M Ruers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Robert KerbelB Kamen
Proceedings of the National Academy of Sciences of the United States of America
Guido BocciRobert Kerbel
© 2022 Meta ULC. All rights reserved